靶向血管内皮细胞治疗胰腺癌的实验研究  

Treatment of pancreatic carcinoma with targeting vascular endothelial cells

作　　者：夏红天[1] 黄志强[1] 袁玫[1] 于占洋[1] 

机构地区：[1]解放军总医院肝胆外科,北京市100853

出　　处：《中华肝胆外科杂志》2003年第8期483-485,共3页Chinese Journal of Hepatobiliary Surgery

摘　　要：目的　运用肿瘤血管内皮细胞的单克隆抗体 ,研究靶向血管内皮细胞治疗胰腺癌的可行性。方法　建立裸小鼠人胰腺癌的动物模型 ,13 1I标记抗胰腺癌血管内皮细胞单抗 ,抑瘤实验。结果　胰腺癌经单纯抗体治疗后 ,抑瘤率为 68 50 % ,经13 1I标记的单抗治疗后 ,抑瘤率为 85 0 6% ,并抑制了转移 ,降低了死亡率 ,病理检查证实 ,经单抗治疗后肿瘤区微血管内血栓形成 ,血管内皮细胞变性、坏死。血管周围大片肿瘤细胞坏死 ,瘤内血管密度明显降低。结论　抗肿瘤血管内皮细胞单克隆抗体在动物实验中对胰腺癌有明显的抑瘤作用 ,以此抗体为载体与核素相结合 。Objective To study the possibility of targeting endothelial cells with the 131 I labeled monoclonal antibody (mAb) for treatment of pancreatic carcinoma. Methods An animal model of human pancreatic carcinoma was established in nude mice and the tumor inhibiting test was conducted with the 131 I labeled mAb. After the mice were killed, the tumor was histologically examined and the intra tumor microvessel density (TMVD) recorded. Results The rate of tumor growth inhibition in mice treated with mAb was 68 50%. After treatment with the 131 I labeled mAb, the rate was increased to 85 06%. Pathologically, massive tumor cell necrosis around the degenerated vessels were observed in the mAb treated mice. TMVD was significantly lower in the mAb treated mice than in those without the treatment. Conclusions The 131 I labeled mAb can exert significant anti tumor effects in the animal model.

关 键 词：血管内皮细胞 靶向治疗 胰腺癌 实验 单克隆抗体 

分 类 号：R735.9[医药卫生—肿瘤] R73-36[医药卫生—临床医学]